

**SPC class wording on the risk of haemolytic anaemia in patients with
glucose-6-phosphate dehydrogenase deficiency**

Agreed by the PhVWP in May 2007

sulfonylurea derivatives:

Section 4.4:

“Treatment of patients with G6PD-deficiency with sulfonylurea agents can lead to haemolytic anaemia. Since <substance name> belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a non-sulfonylurea alternative should be considered.”